Drug firm Alembic Pharmaceuticals on Tuesday said it has received approval from the US health regulator for Fenofibrate tablets, used to lower cholesterol.
The approved product is therapeutically equivalent to the reference listed drug Tricor tablets of AbbVie Inc.
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Fenofibrate tablets in the strengths of 48 mg and 145 mg, Alembic Pharmaceuticals said in a BSE filing.
Quoting IQVIA data, Alembic Pharmaceuticals said Fenofibrate tablets has an estimated market size of USD 94 million for twelve months ending December 2018.
Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
It is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia.
The company currently has a total of 102 ANDA approvals (90 final approvals and 12 tentative approvals) from the USFDA, it added.
Shares of Alembic Pharmaceuticals were trading 1.22 per cent lower at Rs 538.70 apiece on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app